Final answer:
Eltrombopag (Promacta) for the treatment of thrombocytopenia increases the production of thrombopoietin, a hormone that stimulates the development of megakaryocytes into platelets, thereby boosting platelet count.
Step-by-step explanation:
Eltrombopag (Promacta) is a medication used for the treatment of thrombocytopenia, a condition characterized by a low platelet count. Eltrombopag works by stimulating the production of thrombopoietin, a glycoprotein hormone secreted by the liver and kidneys. In essence, Eltrombopag for thrombocytopenia increases thrombopoietin production. This hormone triggers the development of megakaryocytes into platelets, also known as thrombocytes.
Megakaryocytes are large bone marrow cells from which platelets are derived. Eltrombopag's role in stimulating thrombopoietin production accelerates this development process, thus increasing platelet production. It's worth noting that, due to this mode of action, Eltrombopag helps to alleviate the abnormal bleeding associated with thrombocytopenia. The increased production of platelets minimizes the risk of excessive bleeding and promotes proper blood clotting.
Learn more about Eltrombopag